CMHC Press Release

The Changing Landscape of Cardiometabolic Risk: Inflammation, Dyslipidemia, Late-Breaking Clinical Trials and FDA Update Explored at the 8th Annual Cardiometabolic Health Congress


Contact: Brittany Maynard
Tel.: 877.571.4700
E-mail: [email protected]

BOSTON, Sept. 27, 2013-This year’s Cardiometabolic Health Congress (CMHC) will open with the cutting edge research about the pathophysiological connections between inflammation and cardiometabolic disease.

The keynote session, “Inflammation and Cardiometabolic Risk”, by Dr. Peter Libby, will kick off the General Session of the CMHC.

Dr. Libby will discuss the latest research on the science of inflammation, its link to adipose tissue dysfunction, insulin resistance and atherogenic disease, and the implications of this new information on everyday clinical decision-making.

Dr. Libby’s keynote will be followed by the “Late-Breaking Clinical Trials and FDA Update” panel discussion, moderated by Christie Ballantyne, MD.  Each year, the CMHC chairpersons and other noted experts in the field of cardiometabolic health plan this session to help clinicians understand how important clinical trials and FDA actions will affect their practice and patients.
Dr. Ballantyne will be joined by Drs. Deepak L. Bhatt, Robert Eckel, Keith C. Ferdinand, and Jay Skyler to decipher:

CVD Risk in Diabetes: EXAMINE, SAVOR-TIMI 53, VIVIDD, Failure of aleglitazar

Dyslipidemia: ANCHOR, HPS2-THRIVE, FDA approval of mipomersen and lopitamide, Genetics update, HDL-C vs. Triglycerides

Hypertension: AQUARIUS, Safety of hypertension medications, Obesity-related hypertension guidelines

ACS and Thrombosis: CHAMPION PHOENIX, CHAMPION Meta-Analysis, TRILOGY ACS Invasive Analysis, ATLAS-ACS Stent Thrombosis Analysis, ACCOAST

Obesity: Look AHEAD, Intensive Medical Management vs. Roux-en-Y gastric bypass surgery; Newly approved/pending obesity therapies followed by updates to approved drugs

The afternoon keynote session will feature Daniel Rader, MD, presenting: “Translating Insights from Human Genetics into Novel Therapies for Dyslipidemia”

“The CMHC has rapidly become the most illuminating annual forum for updates on the mechanisms underlying the global scourge confronting populations worldwide, and the scientific basis of rational prevention and treatment paradigms,” said Om Ganda, MD 

The 8th Annual CMHC, featuring 74 world-renowned expert faculty, 22 scientific sessions, 22 corporate-supported and sponsored symposia, 42 association supporters and 27.75 CME credit hours, will convene Oct. 2-5, 2013, in Boston. The CMHC provides the most advanced-level cardiometabolic education encompassing a multitude of risk factors, including obesity, Type 2 diabetes, cardiovascular disease, dyslipidemia, atherosclerosis, hypertension, thrombosis, acute coronary syndrome, chronic kidney disease and related comorbidities.

For more information, contact Brittany Maynard at [email protected] or 877-571-4700 or visit


Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.